Clin Osteol 2006; 11(1): 28-29

Phosphatonins - factors regulating phosphate metabolismReview articles

S. Kutilek, S. Skálová

Phosphatonins present a recently discovered group of phosphate-regulating factors. These consist of FGF23, MEPE, FRP4. Pivotal role is also played by PHEX. Disease states associated with phosphatonins are X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR) and tumour-induced osteomalacia (TIO). This review gives basic information on phosphatonins and their effects.

Keywords: phosphate, phosphatonin -hypophosphatemia-FGF 23PHEX, MEPE, FRP4

Published: June 11, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutilek S, Skálová S. Phosphatonins - factors regulating phosphate metabolism. Osteologický bulletin. 2006;11(1):28-29.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 1995;80:1628-34. Go to original source...
    2. Jonsson KB, Mannstadt M, Miyauchi A, et al. Extracts from tumors causing oncogenic osteomalacia inhibit phosphate uptake in opossum kidney cells. J Endocrinol 2001;169: 612-20. Go to original source...
    3. Kumar R. Phosphatonin - a new phosphaturetic hormone? Lessons from tumourinduced osteomalacia and X-linked hypophosphataemia. Nephrol Dial Transplant 1997;12:11-13. Go to original source...
    4. Shimada T, Mizutani S, Muto T, Yoneya T, et al. Cloning and characterization ofFGF23 as a causative factor oftumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5 Go to original source...
    5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associa­ ted with mutations in FGF23. Nat Genet 2000;26:345^8. Go to original source...
    6. Silve C, Beck L. Is FGF23 the long sought phosphaturic factor phosphatonin? Nephrol Dial Transplant 2002;17:958-61. Go to original source...
    7. Tenenhouse HS, Sabagh Z. Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch - Eur J Physiol 2002; 444:317-26. Go to original source...
    8. Blumsohn A What have we learnt about the regulation of phosphate metabolism? Curr Opin Nephrol Hypertens 2004;13:397-401.
    9. Liu S, Guo R, Simpson LG, Xiao Z, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278:37419-26. Go to original source...
    10. Rowe PS.The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 2004;15:264-81. Go to original source...
    11. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 2003;18:1227-34 Go to original source...
    12. Rowe PS, Garrett IR, Schwarz PM, et al. Surface plasmon resonance (SPF) con­ firms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for im­ paired mineralization in X-linked rickets(HYP) Bone 2005;36:33-46. Go to original source...
    13. Baroncelli GI, Bertelloni S, Sodini F, et al. Genetic advances, biochemical and cli­ nical features and critical approach to treatment of patients with X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 2004;1:361-79.
    14. Cho HY, Lee BH, Kang JH, et al. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 2005;58:329-33. Go to original source...
    15. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003;285:1-9. Go to original source...
    16. Velayoudom-Cephise FL, Vantyghem MC, Wemeau JL. Hereditary hypophospha­ taemia in adults. Presse Med 2005;34:1720-6.
    17. Dunstan CR, Zhou H, Seibel MJ. Fibroblast growth factor 23: A phosphatonin regulating phosphate homeostasis? Endocrinology 2004;145:3084-6 Go to original source...
    18. White KR, Larsson TM, Econs MJ. The roles of specific genes implicated as cir­ culating factors involved in normal and disordered phosphate homeostasis: Frp-4, MEPE, and FGF23. Endocr Rev 2006;7:Epub ahead of print.
    19. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24. Go to original source...
    20. Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phospho­ rus homeostasis. Am J Physiol Renal Physiol 2005;289:1170-82. Go to original source...
    21. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005;16:221-32. Go to original source...
    22. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60: 2079-86. Go to original source...
    23. Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia ofbone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:642-6. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.